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ABSTRAK
Transgender adalah satu keadaan biopsikososial yang kompleks dan merupakan 
sebahagian daripada dimensi seksualiti manusia. Ia merangkumi komponen 
kognitif-emosi dan tingkah-laku yang membuatkan seseorang insan itu unik di 
dalam ekspresi seksualitinya. Kaum transgender cenderung untuk menggunakan 
hormon-silang-seks untuk mengubah keadaan dirinya menyerupai gender 
bertentangan yang diingini dengan cara menutupi ciri sekunder seksnya. Seks 
hormon yang biasa digunakan ialah: ““Female to Male Treatment Options (FMTO)” 
iaitu testosterone and hormon wanita pada “Male to Female Treatment Options 
(MFTO)”, di mana kombinasi estrogen dan anti-androgen digunakan. Hormon-
silang-seks iaitu FMTO, atau MFTO mempengaruhi sifat biologi dan psikologi 
individu transgender. Namun begitu, hormon-silang-seks mempunyai profil 
kesan sampingan tertentu yang juga memberi impak biologi dan psikologi. Impak 
psikologi menjurus kepada masalah kesihatan mental dan bunuh-diri.  Pelbagai 
tahap pengaruh biopsikososial kesan hormon-silang-seks diterangkan dan ulasan ini 
memberi ruang membincangkan kepelbagaian pilihan rawatan. Di dalam psikiatri, 
perubahan biologi memberi pengaruh yang besar ke atas individu transgender, 
terutamnaya dari aspek psikososial dan budaya.
Kata-kunci: hormon-silang-seks, kemurungan, keresahan, masalah psikiatri, 
transgender 
ABSTRACT
Transgender is a complex state of bio-psycho-social dimension of human sexuality. 
It encompasses cognitive-emotional-behavior component that makes the person 
unique in his or her sexual expression. Transgender tend to use cross-sex hormone 
in order to eradicate their secondary sexual characteristics and to facilitate the 
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shift to their experienced gender. The common masculinising sex hormone use, 
i.e. Female to Male Treatment Options (FMTO) is testosterone and for feminising 
hormone i.e. Male to Female Treatment Options (MFTO) is a combination of 
estrogen with anti-androgen, respectively. Cross-sex hormone, i.e. FMTO, or 
MFTO has biological and psychological influences on the transgender individuals. 
Nevertheless, cross-sex hormone may also pose a range of side effect profiles, 
varies from the biological to psychosocial impact. The psychological impact can 
be paramount until it causes severe mental-health problems and even suicide. 
Numerous ranges of bio-psycho-social influence of cross-sex hormone were 
highlighted in this review as fundamental core knowledge in the art to know 
practice when dealing with the treatment options. In psychiatry, the change in 
the biological appearance may have great influence in the transgender individual, 
especially in the context of psychosocial and cultural perspective.  
Keywords: anxiety, cross-sex hormone, depression, psychiatric co-morbidities, 
transgender
‘sexes’’ as the same entities, but it is not, 
and commonly leads to misconception 
and misuse of terms. Gender is used 
within the context to the role within 
the society whereas sex is used in 
the context of reproductive capacity. 
So, gender identity is more like a 
social identity and gender dysphoria 
is a descriptive term of an individual’s 
cognitive or affective discontent due 
to the incongruence of one’s allocated 
gender with their experienced gender 
(APA 2013). Another new term which 
emerged from transgender activism 
is cisgender which can be used to 
describe individuals who is on the 
same side (cis-) as their birth assigned 
sex whereas transgender is on the other 
side (trans-) of their birth-assigned 
sex. This term was used to prevent 
marginalization of transgender and it is 
thought to be a positive identification 
by using terms likes cisgender, ‘cisman’ 
or ‘ciswoman’ alongside with the 
INTRODUCTION
The word “transgender” was first coined 
in the 1980s by Virginia Prince when 
referring to gender variant individuals 
(Prince 2005). Transgender is a term 
used when a person has discordant 
among their assigned gender at birth 
with their gender identity. Regarding 
the term ‘transsexual’, it is used for 
individuals who underwent or sought 
transition from male to female and vice 
versa mainly via cross-sex hormone 
management or sex reassignment 
surgery (Prince 2005; American 
Psychiatric Asociation 2013). The 
word ‘transvestite’ is a Latin word and 
it means cross-dresser was coined by 
Hirschfeld. It originally refers to the 
heterosexual cross-dresser, and it is a 
gender manifestation and not a sexual 
manifestation. In other words, a true 
transvestite is not a homosexual (Prince 
2005). Many presumed ‘gender’ and 
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usage of transgender, ‘transman’ or 
‘transwoman’ (Aultman 2014). 
 Previously, the term gender identity 
disorder was used according to 
Diagnostic and Statistical Manual of 
Mental Disorders IV (DSM-IV) and now 
it has changed to gender dysphoria in 
the latest DSM-5 (APA 2013). The core 
features listed were the strong desire 
to be of opposite sex with preference 
to cross-dress and sturdy desire to 
have their sexual characteristics that 
matches one’s experienced gender. 
It is controversial whether to include 
gender dysphoria into DSM as there are 
a lot of debates, whether transgender is 
a pathological condition or it is just a 
natural variation. In DSM-5, the word 
‘disorder’ was removed. Gender-
related dysphoria is a major criterion 
for limiting the diagnosis to those 
who have significant distress for their 
cognitive and affective component. 
This is to focus on the dysphoria as the 
clinical misfortune instead than on the 
identity itself. Not all individuals are 
distressed with their inconsistency of 
assigned gender. This nomenclature 
approach is an attempt to reduce 
psychiatric stigma and discrimination 
on transgender population. The main 
challenge encountered by a physician 
is diagnosing, and treating individuals 
with gender identity disorder, or gender 
dysphoria (Coleman et al. 2012).
 There are few formal epidemiological 
studies on the transgender population 
which makes it difficult to know the 
accurate prevalence of transgender. 
Estimation on the prevalence of 
transgender varies widely, and it 
also depends upon the definition of 
transgender and also the population 
being studied. It was reported that a 
child with gender identity disorder 
had diverse clinical presentation of 
gender identity/orientation disorder 
(Coleman et al. 2012; Zucker 1985) 
where homosexual/bisexual formed 
a majority of presentations, i.e. 46% 
(Figure 1). It is interesting to note that 
about 1/4 of the children studied in 
this long-term follow-up fall under 
a category of the uncertain group 
of neither homosexual/bisexual, 
transsexual, heterosexual nor 
transvestite.
 Earlier researchers described the 
prevalence of transgender to vary from 
1:12,000 to 1:45,000 for transgender 
females and approximately 1:30,000 
to 1:200,000 for transgender males (De 
Cuypere et al. 2007). Few other studies 
showed even higher prevalence of 
transgender depending on the type of 
methodology used. From a population-
based household probability study of 
Figure 1: Long term follow-up studies of children 
with gender identity disorder and psychosexual 
outcome of these groups of children (Zucker 
1985)
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28000 adults in 2010 in Massachusetts 
showed that 1 in 215 people were 
identified as transgender (De Cuypere 
et al. 2007).
 Cross-sex hormone treatment use 
feminizing hormones on individuals 
who are assigned as male at birth and 
vice versa with the use of masculinizing 
hormones on individuals who are 
assigned as female at birth (Coleman 
et al. 2012). The main reason for 
transgender motivating to seek for 
cross-sex hormone is to eradicate most 
of their secondary sexual characteristics 
and also to attain the characteristics of 
the opposite gender (Colton et al. 2011). 
However, data on the therapeutic 
approach is scarce and there is lack of 
consensus on the treatment approach 
for different countries (Coleman et 
al. 2012). So, uncertainties in this 
specialized field of transgender 
medicine may make it difficult for 
this group of individuals to get the 
opportunity to receive appropriate 
treatment which may predispose 
them to suffer from discrimination and 
harmful social conditions. In order to 
help these group of individuals, it is 
necessary to probe further into more 
research to support current guidelines. 
As it is their rights in these population 
to get treatment without prejudice. 
With more interventions developed 
for these vulnerable population may 
help to reduce further victimization, 
violence or stigma in these population 
(Chakrapani et al. 2019; Gonzales & 
Henning-Smith 2017). James et al. 
reported that about 58% of transgender 
individuals had experienced 
discrimination which included loss 
of job, eviction, bullying, physical 
harassment and even denial of access 
to medical services (James et al. 2017). 
Transgender individuals were found 
to be have higher unemployment rate 
and poverty issues compared to non-
transgender counterparts. (Conron et 
al. 2012)
NEUROBIOLOGY IN 
TRANSGENDER
To date, there is paucity of data that 
provides credible information on 
etiology of transgenderism and no 
single factor has been proven with 
certainty that causes gender identity 
disorder (Cohen-Kettenis & Gooren 
1999). Based on previous twin studies, 
it shows that there are strong genetic 
inheritance components of 62% 
for individuals with gender identity 
disorders in early development (Swaab 
2004). Factors which influence the 
development of transgenderism are 
chromosomal disorders such as 
Klinefelter disorder, phenobarbital 
exposure during fatal developmental 
stage, and endocrine disorder (i.e. 
congenital adrenal hyperplasia, 
CAH) (Swaab 2004; Savic et al. 
2010). However, only a small group 
of transgender have underlying 
endocrinology abnormalities (Swaab 
2004; Savic et al. 2010). There were 
observations, which described 
possibility of abnormalities in the 
hypothalamus-pituitary-gonadal 
axis (Figure 2) in transgender as 
evidenced by a higher incidence of 
polycystic ovarian disease (PCOS) and 
menstrual cycle irregularities in female 
to male transgender (Swaab 2004). 
An earlier research found that males 
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had more androgen staining (AR) in 
the hypothalamus, especially in the 
medial and lateral mammillary bodies 
(Swaab 2004).  Other nuclei within the 
hypothalamus such as the preoptic, 
periventricular and supraoptic nucleus 
were also shown to have the sex 
differences in AR staining, which is 
dependent on circulating androgen 
levels (Swaab 2004).  It was observed 
in animal studies that lesions in pre-
optic area in hypothalamus caused 
shift in sexual orientations.
 It has been hypothesized that 
atypical sexual differentiation results 
in gender dysphoria with the physical 
sexual characteristics growing in 
one direction and with the brain 
and gender identity growing in the 
opposite sexual directions (Savic et al. 
2010). The basis behind this theory is 
that during the prenatal period, there 
is a different sensitivity window for 
sex hormone for the brain and sexual 
organs (Savic et al. 2010; Berenbaum 
& Beltz 2011). Sexual development 
for the genitals and brain occurred 
at different stages with the genital 
differentiation in the first two months 
of fetal development. Subsequently 
in the second and third trimester of 
pregnancy, the differentiation occurred 
independently and may result in 
transgenderism (Savic et al. 2010).  
 Few studies showed that 
transgender’s brain is different from 
their natal sex member’s brain and 
more alike to the opposite sex (Savic 
et al. 2010; Swaab & Fliers 1985).  
Transgender’s brain seemed to move 
more towards their experienced 
gender while receiving hormonal 
treatment (Gooren et al. 2015). This 
evidence showed that the brain 
organisation may be under influence 
of prenatal sex hormone, which plays 
a role in the development of the 
neural circuit (Berenbaum & Beltz 
2011; Slabbekoorn et al. 1999). These 
organisational effects are permanent 
and may not depend on subsequent 
hormone influences (Slabbekoorn et 
al. 1999). 
 Studies conducted over three 
decades described the human brain 
with the possibility of morphological 
sex differences (Swaab & Fliers 1985). 
Many observations failed to be 
replicated due to different methodology 
and sampling technique (Swaab & 
Fliers 1985). It has been observed 
that there are sexual differences in 
the shape of corpus callosum and 
suprachiasmatic nucleus (Swaab & 
Fliers 1985). The preoptic area, which 
is involved in gonadotrophin hormone 
release and sexual behaviour were 
found to be sexually dimorphic (Swaab 
& Fliers 1985). In this study, it was found 
that the sexually dimorphic nucleus 
was 2.5 +/- 0.6 times larger, and it 
contained 2.2+/-0.5 times as many 
cells in men (Swaab & Fliers 1985). 
Several studies also showed that sex 
hormone influenced verbal and spatial 
ability with androgen hormone favours 
visuospatial ability and oestrogen 
favours verbal fluency (Gooren et al. 
2015; Slabbekoorn et al. 1999).
 Few women who were subjected 
to diethylstilbestrol (DES) or children 
who have congenital adrenal 
hyperplasia (CAH) were observed to 
have masculinising effect. Such as 
a masculine pattern of lateralisation 
which shows right ear advantage in 
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the dichotic listening task in DES-
exposed women and masculine 
cognitive pattern is seen in women 
with CAH in both spatial and verbal 
tasks (Slabbekoorn et al. 1999). Studies 
stated that three children born were 
transsexuals, and a few of the children 
had gender dysphoria symptoms 
in a group of children who had in-
utero exposure to diphantoin and 
phenobarbital (Swaab 2004; Dessens 
et al. 1999). 
 Based on previous studies, there are 
significant relationships between sex-
role identities with a serum testosterone 
level (Baucom et al. 1985). It has 
been shown that feminine-sex-typed 
women had lowest concentration of 
testosterone compared to masculine-
typed women had been higher level 
of testosterone level (Baucom et al. 
1985). Baucom et al. also noted that 
females with higher testosterone 
levels perceived themselves as 
more resourceful, independent 
and goal directed. Women with a 
lower testosterone level described 
themselves as traditional females being 
more cared, anxious and dejected 
mood (Baucom et al. 1985).
PHYSIOLOGY OF SEX 
HORMONE
Figure 2: Hypothalamo-pituitary-gonadal axis highlighted the summary of regulation and feedback 
mechanism in reproduction for male and female from the higher mental centre [i.e. hypothalamus 
and anterior pituitary]. Gonadotrophin releasing hormone (GnRH) is produced in the hypothalamus 
which control secretion of luteinising hormone (LH) and follicle stimulating hormone (FSH) via the 
hypothalamic-pituitary hypophyseal portal system. LH and FSH stimulate target reproductive organs 
to produce sex hormone (i.e. progesterone, oestrogen and testosterone) for reproductive function 
such as spermatogenesis and development of secondary sexual characteristics. The sex steroid 
hormone together with FSH and LH will have negative feedback on the higher mental centers. 
Inhibin is being produced by Sertoli Cells and it acts on the anterior pituitary to suppress FSH 
release. Numerous neuromodulators are acted as inducer for GnRH release, i.e. norepinephrine 
(NE), neuropeptide Y (NPY) and glumate, whereas γ-aminobutyric acid (GABA), beta-endorphin and 
corticotrophin releasing hormone (CRH) play a role acted as inhibitory factors (Hall 2015; Rhoades 
et al. 2003). The dotted line indicate negative feedback respond. 
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Testosterone is cholesterol based 
steroid hormone, which has a 
diverse effect throughout the body 
as androgen receptors are widely 
distributed (Baucom et al. 1985; 
Zitzmann & Nieschlag 2001). Hence, 
testosterone can have both physical 
and psychological effects in the body. 
Interstitial cells of Leydig produce 
testosterone in the testicles (Hall 2015; 
Rhoades & Tanner 2003). Its production 
and the serum levels are being regulated 
by complex mechanism, which can be 
affected by both the endogenous and 
environmental factors (Hall 2015).
 Figure 2 showed  hypothalamus 
liberates gonadotrophin releasing 
hormone (GnRH) to the vascular 
pituitary gland in order to stimulate 
the secretion of follicle stimulating 
hormone (FSH) and luteinising 
hormone (LH) (Hall 2015; Rhoades 
& Tanner 2003). LH signal Leydig’s 
cells to produce testosterone, which 
leads to development of male 
sexual characteristics (Hall 2015; 
Rhoades & Tanner 2003). However, 
the negative feedback mechanism 
and the complex interplay between 
the hypothalamic-pituitary-gonadal 
axis are still not fully understood 
due to its complexity (Baucom et al. 
1985; Zitzmann & Nieschlag 2001; 
Rhoades & Tanner 2003). Testosterone 
has both androgenic and anabolic 
functions (Hall 2015). Regarding its 
androgenic function, it is mainly 
responsible for the development of 
masculine characteristics. During 
fetal development at the 7th week 
of embryonic life, XY chromosome 
causes the gonadal ridge to secrete 
testosterone and later the testes would 
take over the function of secreting 
testosterone (Hall 2015). Male body 
characteristics such as penis, scrotum, 
prostate gland, seminal vesicles and 
male genital ducts are thus formed. At 
the same time, it also acts to suppress 
the formation of female genital organs 
in the fetus (Hall 2015). 
 Thereafter, testosterone is essentially 
not produced during childhood until 
about 10 to 13 years of age when the 
testosterone production starts again at 
puberty with the stimulus coming from 
the anterior pituitary gonadotrophic 
hormones (Hall 2015). Testosterone 
production continues throughout life 
until after 50 years of age, the level of 
testosterone drops to about 20 to 50% 
of the peak value reaches by 80 years 
of age (Hall 2015). 
 At puberty, testosterone plays a 
major role in adult primary sexual 
characteristic development (Hall 2015; 
Rhoades & Tanner 2003). Testosterone 
can influence the testes, penis and 
scrotum to enlarge up to be eight-
fold before the age of 20 years (Hall 
2015; Rhoades & Tanner 2003). Apart 
from that, testosterone is also involved 
in secondary sexual characteristic’s 
development, which can distinguish 
a male from a female (Hall 2015; 
Rhoades & Tanner 2003). Body 
hair distribution in male is different 
compared to female such as growth of 
hair at the pubic region which goes up 
to the umbilicus along the linea alba of 
the abdomen, increased facial hair and 
hair on the chest or even the back (Hall 
2015; Rhoades & Tanner 2003; Irwig 
2017). Apart from that, testosterone 
also plays a role in hypertrophy of the 
laryngeal mucosa and enlargement of 
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the larynx causing gradual changes 
into masculine voice (Zitzmann & 
Nieschlag 2001; Hall 2015; Irwig 2017). 
Testosterone also causes significant 
changes in increasing thickness of 
the skin, increased ruggedness of the 
subcutaneous tissue and increases 
sebaceous gland activities, which 
may contribute to the acne problem 
(Irwig 2017). Over time, the skin slowly 
adapts to testosterone to overcome the 
acne problem (Hall 2015). 
 Regarding the musculoskeletal 
changes, testosterone is increased 
in muscle mass up to 50% more 
than that of the female counterparts 
(Hall 2015).  It also affects the bone 
growth by increasing the bone matrix 
and intensifies calcium retention, 
which ultimately increases the size 
and strength of the bone (Rhoades 
& Tanner 2003; Irwig 2017). Other 
specific changes related to testosterone 
hormone are narrowing and 
lengthening of pelvic outlet, which 
causes funnel-like shaped pelvis (Hall 
2015). These changes are as a result of 
increased protein level due to anabolic 
function of testosterone, and also due 
to the calcium deposition (Hall 2015).
 Testosterone also plays a role in basal 
metabolic rate, which probably is due 
to protein anabolism whereby surge 
in protein would increase enzymatic 
function and activities of all cells (Hall 
2015). Other changes observed are 
increased in the number of red blood 
cells, blood volume and extracellular 
fluid volumes in males (Hall 2015).  
 Basically, most sexual changes 
caused by testosterone are the 
effects of increased rate of protein 
synthesis in the target cells (Hall 2015).  
Intracellularly, testosterone is mainly 
converted to dihydrotestosterone, 
and then it will induce DNA-RNA 
transcription to increase cellular 
protein production (Hall 2015).  Once 
physical maturity is achieved, basically 
testosterone plays a role in homeostatic 
function by sustaining secondary 
sexual characteristics, continuous 
spermatogenesis, sexual function and 
maintains the muscle bulk.
ESTROGEN
Regarding the female counterpart, 
estrogens are primarily secreted in the 
ovaries from cholesterol and acetyl 
coenzyme A (Hall 2015).  Primary 
function of estrogen is mostly on the 
reproductive system which is growth 
of the tissues and cellular proliferations 
on the reproductive organs (Hall 
2015; Rhoades & Tanner 2003).  
Main carrier proteins for estrogen are 
plasma albumin and specific estrogen 
binding globulins, and they are bound 
loosely, which enable them to be 
rapidly released to the target tissues 
quickly (Hall 2015; Rhoades & Tanner 
2003). Liver is involved in estrogen 
degradation via conjugation, and most 
of its by-products are excreted in the 
bile and some in the urine (Hall 2015; 
Rhoades & Tanner 2003).
 In childhood, serum estrogen level is 
low and during puberty, the secretion 
of estrogen can be influenced by 
the anterior pituitary gonadotrophic 
hormones causing it to increase up to 
20 folds or more (Hall 2015). This results 
in the enlargement of the reproductive 
organs and external genitalia and 
additionally there will be fat deposition 
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in the mons pubis and labia majora 
(Hall 2015; Rhoades & Tanner 2003). 
Regarding the uterine endometrium, 
there is important development, which 
is crucial to prepare female individuals 
for pregnancy later on, which are 
developments of endometrial glands 
and proliferation of the endometrial 
stroma (Hall 2015).
 The changes are also seen in the 
fallopian tube with increment of 
glandular tissue’s proliferation of the 
lining and also increase of ciliated 
epithelial cells, which are involved 
in propelling fertilized ovum to the 
uterus during pregnancy (Hall 2015). In 
addition to it, estrogen changes vaginal 
epithelium from the cuboidal cell 
epithelium in the pre-pubertal period 
to stratified type for it to be more 
resistant to trauma and infection (Hall 
2015). 
 Regarding the secondary sexual 
characteristics, estrogen is involved in 
development of breast tissues together 
with growth of the ductile system in the 
breasts (Hall 2015; Rhoades & Tanner 
2003). Estrogen also leads to increase 
in fat deposition in the breasts (Hall 
2015). Estrogen inhibits osteoclastic 
activity in the bones which stimulates 
skeletal growth (Hall 2015). During 
menopause when there is virtually 
no estrogen secretion, osteoporosis 
is a common condition seen leading 
to weakening of bones and risk of 
fractures (Hall 2015; Rhoades & Tanner 
2003). 
 When compared to testosterone, 
estrogen only causes a slight increase 
in protein position and basal metabolic 
rate (Hall 2015). Estrogen also causes an 
increase in fat deposition, which forms 
a characteristic female figure with fat 
deposition at the breast, subcutaneous 
tissues, thighs and buttocks (Hall 
2015; Rhoades & Tanner 2003). Other 
effects of estrogen include the soft and 
smooth skin texture compared to the 
males (Hall 2015). 
PROGESTERONE
Progesterone is the most important 
progestin and it is produced normally 
by the corpus luteum at the second 
half of the menstrual cycle (Hall 2015). 
When progesterone is secreted, it is 
converted to other steroids quickly 
and liver plays a role in degradation 
of progesterone (Hall 2015; Rhoades & 
Tanner 2003).
 The main function of progesterone 
in sexual development is secretory 
change in the uterine endometrium 
in order to prepare for fertilisation 
to take place (Hall 2015; Rhoades & 
Tanner 2003). Regarding the breast 
development, progesterone plays a role 
in alveolar cell proliferation to prepare 
the breast for its secretory function 
(Hall 2015; Rhoades & Tanner 2003). 
However, milk production only occurs 
with stimulation of prolactin hormone 
(Hall 2015; Rhoades & Tanner 2003).
CRITERIA TO START CROSS-SEX 
HORMONE
There are different criteria, which 
must be fulfilled before allowing 
an individual to start on cross-sex 
hormone therapy (Coleman et al. 
2012; Irwig 2017). These criteria can be 
obtained from the World Professional 
Association for Transgender Health, 
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Standard of Care, version 7, WPATH 
SOC 7, i.e. for obtaining informed 
consent and the initial visits, assessment 
and intervention (Cavanaugh 2016). 
WPATH recommends that cross-sex 
hormone therapy can be initiated 
once psychosocial assessment has 
completed by a qualified mental 
health professional unless the 
prescribing provider is also qualified 
to perform this type assessment. After 
that the individual is deemed to be 
an appropriate candidate to go for 
hormone therapy and after obtaining 
the informed consent for treatment 
(Unger 2017).  
 It must be well documented that 
an individual has persistent gender 
dysphoria which was diagnosed by a 
mental health professional who is well 
versed in this field and the individual 
must have the capability to make an 
informed decision and give consent 
for the therapy. If the individual has 
significant medical or psychiatric 
comorbidity, it must be reasonably 
properly controlled (Coleman et al. 
2012; Irwig 2017). There is also a 
minimum age for medical consent, 
and if the individual is a child or of 
adolescent age, there is a need for 
the individual’s parents or caretaker 
to give consent and to be involved 
in supporting the individual during 
the treatment process (Coleman et al. 
2012). 
 In the past four decades, real-life 
test (RLT) or real-life test experience 
(RLE) has been practiced which was 
likely derived from Dr. Harry Benjamin 
and subsequently it was reinforced by 
series of expert opinion through the 
revisions of Standards of Care (Levine 
2009). However, there was lack of 
scholarly evidence or research ever 
done on it to support these practices 
and it was mainly based on level of 
expert opinion. So, there was lack of 
evidence to address its issues such as 
duration of real-life test, the purpose 
of test or assessment to use which 
sparks criticism and controversy of this 
practice. RLT is an extended period 
where individuals live as a member 
of desired sex full time prior to some 
irreversible social, medical or surgical 
step taken (Levine 2009). This practice 
gives the individual an opportunity to 
experience and to test their personal 
belief that life would be subjectively 
be better when they occupy their new 
gender role full time (Levine 2009). RLT 
would generally test the individual’s 
conviction, courage and adaptive 
challenge in their daily life. 
PHARMACOLOGICAL 
INFLUENCE AND 
INTERVENTION: CROSS-SEX 
HORMONE
Cross-sex hormone administrations 
of exogenous hormonal preparations, 
which lead to feminizing or 
masculinizing effects on the body. This 
treatment should be individualized 
based on individual’s needs with 
consideration on patient’s patient’s 
background medical co-morbid, 
psychosocial issues and risk-benefit 
weighting of the treatment to the 
patient (Coleman et al. 2012). There is 
a wide variation of hormonal treatment 
with a different diversity of doses 
available in the market (Coleman et 
al. 2012). Currently, with the newer 
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transdermal preparations and the 
approach of using low doses may help 
to reduce adverse reactions, but it is 
still a concern for healthcare providers 
and patients (Coleman et al. 2012). To 
date, there is lack of study on the cross-
sex hormone in transgender which is 
a major setback on gender affirmation 
treatment in transgender (Coleman et 
al. 2012). Another limitation noted is 
that it is different in countries and would 
vary in terms of availability of cross-sex 
hormone therapy. Fewer transgender 
even opted to take hormonal therapy 
without medical supervision as some 
parts of the world still have barriers 
in accepting transgender (Irwig 2017). 
Due to social stigma, lack of cultural 
acceptance and poor awareness on 
transgender, suboptimal transgender 
care is common (Coleman et al. 2012).
MASCULINISING HORMONE 
THERAPY (FEMALE TO MALE 
TREATMENT OPTIONS, FMTO)
TESTOSTERONE
Testosterone hormone comes in many 
different formulations such as oral, 
topical, transdermal and intramuscular 
form. The oral testosterone undecanoate 
can be given between 160 mg-240 mg 
OD, testosterone enanthate 50 mg to 
200 mg weekly given intramuscularly 
or subcutaneously. For transdermal 
patch, the dosing can be between 25 
mg to 75 mg daily and testosterone 
1% gel at 25 mg to 100 mg daily. The 
main aim is to use the lowest possible 
dose to achieve masculinising effects 
in patients and have to balance it with 
its potential adverse reactions (Irwig 
2017). This treatment generally is quite 
similar to treatment of hypogonadal 
males and the testosterone level 
should be increased to achieve normal 
male’s physiological range which is 
between 300 to 1000 ng/dL (Webb & 
Safer 2019).
 There is no standard practice 
which can guide on the starting and 
maintaining dose. Usually, it is initiated 
at a low dose first and then gradually 
step up the dose with periodic 
monitoring of serum testosterone level 
to guide titration (Coleman et al. 2012). 
Testosterone therapy will change the 
body composition of fat and muscle 
bulk towards natal men (Colton et al. 
2011). Usually, the agent of choice for 
testosterone would be intramuscular 
testosterone such as cypionate (Colton 
et al. 2011).
 In the first year of treatment, patient 
is recommended to be monitored every 
3 months to assess on the virilising 
effect and thereafter can be 6 monthly 
to yearly follow up. During each visit, 
it is recommended to monitor patient’s 
serum testosterone level, hematocrit 
and lipid profile with a baseline result 
prior to starting hormonal therapy. 
Other screenings that should be done 
are bone mineral density, pap smear 
and mammography for patients with 
cervixes and breasts (Coleman et al. 
2012; Webb & Safer 2019).
OTHER AGENTS
Progestins may be used to help in 
cessation of menstruation (Hall 2015)
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FEMINISING HORMONE 
THERAPY (MALE TO FEMALE 
TREATMENT OPTIONS, MFTO)
Feminising hormone therapy is 
slightly more complicated than the 
regimen for masculinizing hormone 
therapy as female transgender requires 
antiandrogen in addition to estrogen. 
The main goal of treatment would be 
to aim for female range of testosterone 
level which is less than 100 ng/
dL and be cautious to avoid supra-
physiological levels of estradiol which 
is to keep it below 200 pg/mL breasts 
(Coleman et al. 2012; Webb & Safer 
2019; Gardner & Safer 2013).
 It was recommended that female 
transgender to have regular follow 
up every 3 monthly for the first year 
of initiation of therapy to monitor the 
feminizing effect as well as to watch 
out for any adverse effects (Webb 
& Safer 2019). Baseline lipid profile, 
serum prolactin should be obtained 
prior to therapy and then repeated 
during every visit together with serum 
testosterone and estradiol with the 
aim to maintain it between the range 
of testosterone at 30 to 100 ng/dL and 
estradiol less than 200 pg/ml (Webb 
& Safer 2019; Gardner & Safer 2013). 
Other important surveillance would 
bone density test, screen for cancers, 
metabolic syndrome including 
monitoring of weight and also look for 
gallstones if clinically indicated (Webb 
& Safer 2019; Gardner & Safer 2013).
ESTROGEN
There are a few routes of 
administration, i.e. oral, transdermal 
form and parenteral estradiol valerate. 
However, oral estrogen, notably 
ethinyl estradiol is not advisable as 
there is an increased risk of venous 
thromboembolism (VTE) (Coleman 
et al. 2012). Due to safety concerns, 
transdermal is recommended and VTE 
is dose-related, so if possible, it is better 
to start at lower doses, particularly in 
individuals at risk to get VTE (Moore 
et al. 2003). Usually, the dose used for 
feminizing effect is about 2-3 times 
higher than the hormone-replacement 
therapy in post-menopausal women 
(Moore et al. 2003). After the age 
of 40 years, transdermal route was 
recommended as it bypass the first-
pass metabolism which seemed to 
have better metabolic profiles (Unger 
2017).
 For oral estradiol it has been 
recommended to keep the dose 
between 2 to 4 mg OD, transdermal 
estradiol was between 0.1 to 0.4 mg 
biweekly and parenteral estradiol 
valerate was 5 to 30 mg once every 
fortnightly (Unger 2017).
ANTI-ANDROGEN
Primary objective of anti-androgen is 
to reduce the effect of endogenous 
testosterone activity to reduce 
masculine characteristics. Most studies 
suggested for combination of anti-
androgen with estrogen for feminizing 
effects, and this combination may be 
the lower dosage of estrogen needed 
to reduce testosterone activity, which 
can reduce estrogen related adverse 
effects (Moore et al. 2003). So far, there 
are no consensus guideline on usage 
of anti-androgen (Unger 2017).
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 Anti-androgen came from a wide 
variety of different drug classes 
and below are the common anti-
androgen drugs being used currently: 
(i) Spironolactone is one of the 
commonest drug being used which is 
a type of antihypertensive drugs that is 
known to directly inhibit testosterone 
secretion and binding of androgen to 
the androgen receptor (Aultman 2014). 
The dose being used commonly was 
between 100 to 200 mg OD and 
patients need to be monitored closely 
for hyperkalemia (Unger 2017), (ii) 
Cyproterone acetate is a synthetic 
compound of 17-hydroxyprogesterone 
and it was shown to have anti-androgen 
properties. It mainly acts as an 
androgen receptor antagonist (Wierckx 
et al. 2012)., (iii) GnRH agonists are 
neurohormones, which comes in 
injectable forms or implants are a 
more expensive form of treatment. The 
GnRH agonist inhibits the release of 
follicle stimulating hormone (FSH) and 
luteinizing hormone (LH). It functions 
as a highly effective form of gonadal 
blocking (Coleman et al. 2012). GnRH 
agonist (leuprolide) can be given 
between 3.75 to 7.5mg intramuscularly 
every month (Unger 2017), (iv) 5-alpha 
reductase inhibitors, i.e. finasteride 
and dutasteride are known to inhibit 
testosterone from converting to its 
active form, which is the 5-alpha 
dihydrotestosterone (Coleman et al. 
2012). Finasteride dosing commonly is 
1 mg OD (Unger 2017). 
PROGESTIN
Progestin usage is rather controversial 
as its usage was found that it did 
not enhance growth of breast tissue 
or lower down testosterone level 
(Coleman et al. 2012). In addition to it, 
progestins have an increase in risk for 
pulmonary embolism, coronary artery 
disease, cerebrovascular accidents and 
breast cancer risk, especially when 
used in combination with estrogen 
(Coleman et al. 2012). The dose for oral 
Figure 3: List of possible physical effects of cross sex hormones in transgender.
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Progesterone was between 20 mg to 60 
mg OD (Unger 2017). Figure 3 shows 
the list of possible physical effects of 
cross sex hormones in transgender.
BIOLOGICAL INFLUENCES IN 
TRANSGENDER
Few researchers suggested that 
masculinizing treatment using 
testosterone or other androgenic sex 
steroids may further aggravate affective 
symptoms such as hypomania, mania 
or even psychotic symptoms in 
those individuals with co-morbid of 
psychiatric illness (Coleman et al. 2012; 
Seiger et al. 2016). With regard to the 
testosterone that may boost dopamine 
sensitivity in the brain as an adverse 
effect inducing psychotic disorders, 
studies in these areas of interest 
were contradictory and inconclusive 
(Elias & Kumar 2007; Trotman et al. 
2013). On the contrary, estrogen may 
produce neuroprotective effect against 
psychotic disorders (James et al. 2016; 
Kirkbride et al. 2012; Weickert et al. 
2016).
 These adverse reactions seem to 
occur when there were higher doses or 
supra physiological serum testosterone 
level. However, evidence of such is 
limited and its risk is inconclusive. 
PSYCHOLOGICAL INFLUENCES 
IN TRANSGENDER WITH 
CROSS-SEX HORMONE
Cross-sex hormone was found 
consistently to bring positive effects to 
be transgender psychologically, which 
was replicated in many studies (Colton 
et al. 2011). Regarding female-to-male 
who are on testosterone therapy were 
observed to have improvement in 
quality of life, which was also seen for 
male-to-female counterparts (Gorin-
Lazard 2012). 
MAJOR DEPRESSIVE DISORDER
A low level of estrogen was found 
to be associated with depression, 
which is seen in normal physiology of 
females during their menstrual cycle, 
postpartum period and menopausal 
period. It was found that transgender 
women had higher prevalence 
of depression with an estimated 
prevalence rate to range between 48% 
to 62% and when compared to general 
population in the United States, it was 
about 16.6% (Hoffman 2014; Budge et 
al. 2013). Estrogen was found to have 
a calming effect, and it was used to 
augment the effect of antidepressant 
in patients with depression (Khobzi  
Rotondi 2011).
 There is some evidence, which 
shows that androgen deprivation 
treatment in prostate cancer patients 
are linked to increased rate of 
depression, which may apply to 
male-to-female transgender taking 
anti-androgen treatment (Khobzi 
Rotondi 2011). Studies correlated the 
relationship between gonadal function 
and depressive episodes as it has been 
observed that hypogonadal men on 
testosterone treatment seemed to show 
improvement in the mood (Zitzmann 
& Nieschlag 2001). Cyproterone 
acetate usage has been observed to 
cause transient depressive symptoms 
during the first 6 months of hormonal 
treatment (Asscheman et al. 2011).
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 There are many risk factors apart 
from the hormonal effect which can 
predispose transgenders to depression, 
which are gender dysphoria, lack of 
social support, physical and verbal 
abuse, discrimination, being a sexual 
worker and socio demographic factors 
such as low education level and 
unemployment (Colton et al. 2011; 
Hoffman 2014). 
ANXIETY DISORDER
Regarding anxiety disorder in 
transgender, the rate can range from 
26% to 38% (Budge et al. 2013). 
Gómez-Gil et al. reported findings 
of transgender on cross-sex hormone 
showed to have lower levels of social 
distress, anxiety and even depression 
when comparing with transgender 
who were not on cross-sex hormone 
therapy (Gómez-Gil et al. 2009).
MORTALITY RATE AND SUICIDE
Earlier researchers reported that 
mortality rate for male to female 
group was about 51% higher than the 
general population (Assheman et al. 
2011). However, in the same study, 
regarding relation of female to the 
male group, there was no significant 
difference in the mortality rate in 
comparison to the general population. 
There was increased mortality rate up 
to 8-fold times in the males compared 
to the females and was mainly due to 
non-hormonal related such as illicit 
substance usage, suicide and acquired 
immune deficiency syndrome (AIDS) 
(Assheman et al. 2011).
 Regarding suicide, there was six-
fold increase in the male to female 
subjects, but it was pertinent to note 
that there were other confounding 
factors, which affected the results 
(Assheman et al. 2011). Individuals 
who were transgender, presented 
themselves to the Psychiatry Unit 
with history of suicidal attempts or 
substance abuse or affective disorder 
even prior to cross-sex hormone 
treatment. This was probably related 
to the psychological stress from 
gender dysphoria. Clements-Nolle et 
al. reported prevalence for suicide in 
transgender to be 32% (Colton et al. 
2011; Clements-Nolle et al. 2006). 
PSYCHOLOGICAL AND 
COGNITIVE EFFECTS OF 
CROSS-SEX HORMONE 
THERAPY IN TRANSGENDER
Generally, cross-sex hormone therapy 
can alleviate overall well-being and, 
mainly it reduces gender dysphoria 
irrespective for transgender men or 
transgender women (Colton et al. 
2011). In one longitudinal study, it 
was shown that hormonal therapy 
demonstrated positive effects in 
transgender. The study was conducted 
on the transgender before and after 12 
months of hormonal therapy and it was 
found that their emotions were stable 
using Zung Self-rating Depression Scale 
(SDS) and Zung Self-rating Anxiety 
Scale (SAS) (Colizzi et al. 2014). In 
this prospective study, it showed that 
there are lower psychological distress 
and lesser functional impairment 
with hormonal therapy compared to 
one prior the hormonal treatment. 
The results showed that for anxiety 
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before treatment, it was 50%, and it 
was only 17% following 12 months of 
hormonal treatment. The depressive 
psychopathology was 42% for pre-
treatment group and 23% for those 
following 12 months of hormonal 
treatment. This study also used 
Symptom Checklist 90-R (SCL-90-R) 
to evaluate global psychological 
symptoms. The psychological distress is 
24% at enrolment phase and 11% after 
being on hormonal therapy. Regarding 
functional impairment, it was 23% 
before hormonal treatment and 10% 
after hormonal treatment, respectively, 
using Structured Clinical Interview for 
DSM-IV-TR Axis I Disorders (SCID-I) 
(Colizzi et al. 2014). Current evidence 
on cross sex therapy with regards to 
improving psychological well-being is 
quite encouraging especially for male-
to-female transgender (Nguyen et al. 
2018). 
 In another study by Keo-Meier, 
Minnesota Multiphase Personality 
Inventory (MMPI-2) was used as it was 
believed that MMPI-2 results would 
remain stable even with intensive 
psychotherapy (Keo-Meier et al. 2015). 
This study showed that with 3 months 
of testosterone therapy, there was 
substantial improvement of transgender 
men in depression, hypochondria, 
hysteria and paranoia when compared 
to the female controls. The results 
showed that testosterone therapy in 
transgender men helped to improve 
multiple domains of psychological 
functioning.
 The published data on effects 
of cross-sex hormone therapy to 
the person’s cognition is limited. 
Slabbekkoorn reported that there was 
a significant correlation with androgen 
treatment on spatial ability in female-
to-male (FTM) transgender and these 
effects were not reversed after a five-
week period of termination of androgen 
treatment (Slabbekoorn et al. 1999). 
With regard to testosterone treatment 
option, it has an activating effect which 
is not rapidly reversible on spatial 
ability performance. However, in this 
study, anti-androgen treatment did 
not seem to show a decline in spatial 
ability nor improved in verbal fluency 
in male-to-female (MTF) transgender. 
Most studies to date suggested that 
masculinizing therapy enhances in 
visual memory and 3-dimentional 
spatial memory tasks but worsens 
verbal memory (Nyugen et al. 2018). 
 Studies showed that masculinizing 
therapy increases cortical thickness 
in the parieto-occipito-temporal 
regions may suggest possibility of 
some testosterone-induced structural 
connectivity. As for feminizing 
therapy, some research found that 
there was decreased in cortical 
thickness, decreased in subcortical 
volumetric measures and enlargement 
of ventricular system (Nyugen et al. 
2018; Seiger et al. 2016; Spizzirri et 
al. 2018). Mueller et al. also found 
there was mean neuroanatomical 
volume for the amygdala, putamen 
and corpus callosum differed between 
transgender men and cismen in 
several brain structures including 
medial temporal lobe structures and 
cerebellum. He suggested that there 
is localized influence of sex hormones 
neuroanatomy (Mueller et al. 2017). 
 There was also a relationship 
between estrogens and borderline 
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personality where the latter may be 
adversely influenced by alterations 
in the estrogen levels, especially 
among women (Evardone et al. 
2008). Estrogen regulation on the 
neurotransmitter systems in the CNS 
may explain the affective instability 
associated with borderline personality 
among the sample of women and men. 
Interestingly however, this relationship 
may also be greatly influenced by other 
variables, e.g. age, menopausal and 
genetic make-up and that this could 
potentially influence the interpretation 
of the results involved in this disorder 
(Mc Ewen 2001).
 Generally, the studies to date on 
safety and effects of cross sex hormone 
towards the brain are very few to date 
with most studies limited to small 
sample size and most studies are cross-
sectional in nature. So, future research 
should focus if these neuroanatomical 
changes gives impact to functional or 
cognitive changes as these domains 
are important in daily functioning 
in individuals on hormonal therapy. 
Interestingly, Mohammadi & Khaleghi 
suggested that there is relationship and 
interaction between culture, behavior 
and brain structures. Transgender will 
experience changes in lifestyle and 
beliefs and these changes in new 
culture and concepts may alter brain’s 
function and structure based on the 
culture-behaviour-brain loop model 
(Mohammadi & Khaleghi 2018).
AGGRESSION AND SEXUALITY
Animal studies showed that 
aggressive behaviour is found more 
predominantly in males, and some 
criminological studies showed that 
men use far more physical violence, 
and these studies linked testosterone 
to aggression. These include criminals 
who are involved in violent felonies 
were found to have higher testosterone 
levels compared to felons who were 
convicted for burglary or theft (van 
Goozen et al. 1995).
Figure 4: Summary of cross sex hormones having a role in the bio-psycho-behavioural domains 
(Coleman et al. 2012; Irwig 2017; Cavanaugh 2016; Unger 2017).
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 Regarding FTM treatment options, 
there are positive correlations of 
testosterone with aggression. In 
an earlier study by Slabbekoorn, it 
was shown that FTM who are on 
testosterone therapy have higher 
scores for anger proneness, which was 
replicated in a previous study by Van 
Goozen (van Goozen et al. 1995). In 
this same study, it was found that their 
increased sexual feelings measured 
by frequency of sexual activity after 
being on testosterone therapy for FTM 
and also general reduction in affect 
intensity. Interestingly, in an animal 
study where female rats were injected 
with testosterone, not only showed 
increased in aggressive behaviour but 
also showed an increase in the sexual 
behaviour (van Goozen et al. 1995). 
Based on these studies, it was suggested 
that females are more sensitive to 
minor variations in the circulating 
testosterone levels (van Goozen et al. 
1995). However, there were conflicting 
results in which the administered 
exogenous supra-physiological levels 
of testosterone showed that there was 
no sufficient evidence to suggest link 
between testosterone with increased 
aggression (Anderson et al. 1992; 
O’Connor et al. 2002). 
 We represented the summary of 
cross sex hormones having a role in 
the bio-psycho-behavioural domains 
in Figure 4.
ADVERSE EFFECTS FROM 
CROSS-SEX HORMONES
It has been reported that male to 
female transgender on hormonal 
treatment, experience more 
important adverse effects such as 
thromboembolism, cardiovascular 
event and osteoporosis. However, 
it has been found that female to the 
male transgender group on hormonal 
treatment seemed were relatively safer 
(Wierckx et al. 2012). It was reported 
that 12% of male to female transgender 
experiences thromboembolic or other 
cardiovascular event (Wierckx et al. 
2012). Among the risk that comes 
with cross-sex hormone therapy are 
different for female to male group and 
male to female group. Another area 
to address is to look into possibility of 
sexual dysfunction in this population 
group as changes in level of hormones 
may interfere with sexual functioning. 
Validate questionnaire such as Female 
Sexual Function Index Questionnaire 
(FSFI) may be used during clinic visits 
(Tee et al. 2014; Hatta et al. 2007).
ADVERSE EFFECTS OF FEMALE 
TO MALE TREATMENT WITH 
REGARD TO HORMONAL 
THERAPY  
Testosterone is the main hormone 
used and its adverse reactions are 
weight gain, blunting in the insulin 
receptor sensitivity, worsening of lipid 
profile, and hematocrit elevation. 
These combinations of antagonistic 
reactions have raised the concern for 
possibly increasing the risk of cardiac 
and thrombo-hemolytic events. 
Polycythemia was also reported as 
one of its rarer adverse reactions. 
Other masculinizing hormones 
adverse effects are acne, androgenic 
baldness, sleep apnea and liver 
enzyme derangement (Cavanaugh 
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2016). So, surveillance on metabolic 
syndrome during each follow up with 
basic anthropometric measurement 
may be useful such as weight, waist 
circumference, BMI, blood pressure 
and heart rate on every clinic visit 
apart from regular blood investigations. 
Imaging or further test may be 
necessary if clinically indicated during 
follow up.
ADVERSE EFFECTS OF MALE 
TO FEMALE TREATMENT WITH 
REGARD TO HORMONAL 
THERAPY
Research more than a decade 
(Cavanaugh 2016), reported 20-fold 
increase in the venous thrombosis and 
also an increase in serum prolactin in a 
retrospective morbidity and mortality 
due to feminizing treatment. This 
may possibly increase the growth of 
prolactinomas (Cavanaugh 2016). The 
adverse effects are dose dependent and 
the risk further increased when other 
risk factors were present, e.g. Smoking, 
obesity, and advance age may increase 
the risk for cardiovascular event in 
transgender on feminizing treatment. 
So, regular follow-up is vital to watch 
out for these adverse effects by 
monitoring patient’s metabolic profile 
via anthropometric measurements 
and regular blood monitoring. Further 
investigations should be promptly 
initiated accordingly if patient has 
any early signs of any adverse effects 
(Figure 5). 
CONCLUSION
In summary, cross-sex hormone 
generally gives benefits to be 
transgender, but it may also bring 
deleterious effects such e.g. FTM gets 
reduced in affect intensity, and MTF 
experienced more tension, gloomy 
mood and easy fatigability. The 
present review showed that there are 
Figure 5: Side effects profile of cross sex hormone therapy (Coleman et al. 2012; Cavanaugh 2016).
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few heterogeneous results in some 
studies and one needs to take note 
on limitations in these literature. 
Inconsistent results may be due to 
limitations with methodology such 
as small sample size and issues with 
study design or sample distribution. 
Many definitive questions still 
remain unanswered due to lack of 
retrospective or prospective studies 
on cross-sex hormone. Generally, the 
evidence on cross-sex therapy is of low 
quality due to improper technique of 
randomization and control groups in 
the study performed. So, it is important 
to convey to patients regarding 
potential uncertainty and there is a 
need for individualised treatment 
approach based on risk and benefit 
ratio for each patient. Transgenderism 
is a complex disorder and treatment 
approach is not too easy, and it needs 
an integrated approach of physical, 
psychological, social and even cultural 
interventions. There are many issues 
to address on the care for transgender. 
Limited accesses for healthcare services 
for transgender and lack of trained 
mental health professionals are some 
of the important restrictions. Stigma 
and potential political discrimination 
to these special groups of individuals 
carry significant psychosocial issues 
to not only the transgender, but also 
pose a dilemma to the mental health 
professionals who are dealing with 
this special group of patients. So, it 
is important to educate the scientific 
community regarding treatment 
options that are available and also its 
latest evidence found. As it is important 
to mainstream transgender care 
among medical healthcare workers 
and published transgender medical 
treatment guidelines may provide 
a foundation for more generalized 
patient care and more assessible to for 
transgender population.
ACKNOWLEDGEMENT
The authors acknowledge the support 
by UKM (DLP-2014-009).
REFERENCES
Anderson, R.A., Bancroft, J., Wu, F. 1992. The effects 
of exogenous testosterone on sexuality and 
mood of normal men. J Clin Endocrinol Metab 
75(6): 1503-7.
Asscheman, H., Giltay, E.J., Megens, J.A., de Ronde, 
W.P., van Trotsenburg, M.A., Gooren, L.J. 2011. 
A long-term follow-up study of mortality in 
transsexuals receiving treatment with cross-sex 
hormones.  Eur J Endocrinol 164(4): 635-42. 
American Psychiatric Association. 2013. Diagnostic 
and Statistical Manual of Mental Disorders 
(DSM-5). American Psychiatric Pub.  
Aultman, B. 2014. Cisgender. Transgender Studies 
Quarterly 1(1-2): 61-2.
Baucom, D.H., Besch, P.K., Callahan, S. 1985. 
Relation between testosterone concentration, 
sex role identity, and personality among 
females. J Pers Soc Psychol 48(5): 1218-26.
Berenbaum, S.A., Beltz, A.M. 2011. Sexual 
differentiation of human behavior: effects of 
prenatal and pubertal organizational hormones. 
Front Neuroendocrinol 32(2): 183-200. 
Budge, S.L., Adelson, J.L., Howard, K.A. 2013. Anxiety 
and depression in transgender individuals: the 
roles of transition status, loss, social support, 
and coping. J Consult Clin Psychol 81(3): 545-
57.
Cavanaugh, T. 2016. Cross-sex hormone therapy. In 
Proceedings of the First Advancing Excellence 
In Transgender Health Conference: Boston, MA. 
The Fenway Institute.
Chakrapani, V., Lakshmi, P., Tsai, A.C., Vijin, P.P., 
Kumar, P., Srinivas, V. 2019. The syndemic 
of violence victimisation, drug use, frequent 
alcohol use, and hiv transmission risk behaviour 
among men who have sex with men: cross-
sectional, population-based study in India. 
SSM-Popul Health 3: 7.
Clements-Nolle, K., Marx, R., Katz, M. 2006. 
Attempted suicide among transgender persons: 
the influence of gender-based discrimination 
21
Cross-Sex Hormones in Transgender Med & Health Jun 2019;14(1): 1-22
and victimization. J Homosex 51(3): 53-69.
Cohen-Kettenis, P.T., Gooren, L.J. 1999. 
Transsexualism: a review of etiology, diagnosis 
and treatment. J Psychosom Res  46(4): 315-3.
Coleman, E., Bockting, W., Botzer, M., Cohen-
Kettenis, P., Decuypere, G., Feldman, J., Fraser, 
L., Green, J., Knudson, G., Meyer, W.J. 2012. 
Standards of care for the health of transsexual, 
transgender, and gender-nonconforming 
people, version 7. Int J Transgend 13(4): 165-
232.
Colizzi, M., Costa, R., Todarello, O. 2014. Transsexual 
patients’ psychiatric comorbidity and positive 
effect of cross-sex hormonal treatment on 
mental health: results from a longitudinal study. 
Psychoneuroendocrinology 39: 65-73.
Colton Meier, S.L., Fitzgerald, K.M., Pardo, S.T., 
Babcock, J. 2011. The effects of hormonal 
gender affirmation treatment on mental health 
in female-to-male transsexuals.  J Gay Lesbian 
Ment Health 15(3): 281-99.
Conron, K.J., Scott, G., Stowell, G.S., Landers, S.J. 
2012. Transgender health in massachusetts: 
results from a household probability sample of 
adults. Am J Public Health 102(1): 118-22.
De Cuypere, G., Van Hemelrijck, M., Michel, A., 
Carael, B., Heylens, G., Rubens, R., Hoebeke, P., 
Monstrey, S. 2007. Prevalence and demography 
of transsexualism in Belgium. Eur Psychiatry 
22(3): 137-41.
Dessens, A.B., Cohen-Kettenis, P.T., Mellenbergh, 
G.J., vd Poll, N., Koppe, J.G., Boer, K. 1999. 
Prenatal exposure to anticonvulsants and 
psychosexual development. Arch Sex Behav 
28(1): 31-44.
Elias, A., Kumar, A. 2007. Testosterone for 
schizophrenia. Cochrane Database of Syst Rev 
18(3): CD006197.
Evardone, M., Alexander, G.M., Morey, L.C. 2008. 
Hormones and Borderline Personality Features. 
Pers Individ Dif  44(1): 278-87. 
Gardner, I.H., Safer, J.D. 2013. Progress on the road 
to better medical care for transgender patients. 
Curr Opin Endocrinol Diabetes Obes 20(6): 
553-8.
Gómez-Gil, E., Trilla, A., Salamero, M., Godás, T., 
Valdés, M. 2009. Sociodemographic, clinical, 
and psychiatric characteristics of transsexuals 
from spain. Arch Sex Behav 38(3): 378-92.
Gonzales, G., Henning-Smith, C. 2017. Barriers to care 
among transgender and gender nonconforming 
adults. Milbank Q 95(4): 726-48.
Gooren, L.J., Kreukels, B., Lapauw, B., Giltay, E.J. 
2015. (Patho)physiology of cross-sex hormone 
administration to transsexual people: the 
potential impact of male–female genetic 
differences. Andrologia 47(1): 5-19.
Gorin-Lazard, A., Baumstarck, K., Boyer, L., 
Maquigneau, A., Gebleux, S., Penochet, 
J. C., Pringuey, D., Albarel, F., Morange, I., 
Loundou, A., Berbis, J. 2012. Is hormonal 
therapy associated with better quality of life in 
transsexuals? a cross-sectional study. J Sex Med 
9(2): 531-41.
Hall, J.E. 2015. Guyton and Hall Textbook of Medical 
Physiology E-Book. Elsevier Health Sciences.
Hatta, S., Sharifah Ezat, W.P., Marhani, M., Norni, 
A. 2007. Female sexual dysfunction among 
malaysian women in a primary care setting: does 
the frequency of sexual activity matter? Med 
Health 2(1): 48-57.
Hoffman, B. 2014. An overview of depression among 
transgender women.  Depress Res Treat 2014 
Articel ID 394283
Irwig, M.S. 2017. Testosterone therapy for transgender 
men. Lancet Diabetes Endocrinol 5(4): 301-11.
James, S., Herman, J., Rankin, S., Keisling, M., Mottet, 
L., Ana, M. 2017. The Report of the 2015 US 
Transgender Survey. 2016. Washington, DC, 
The National Center for Transgender Equality.
Keo-Meier, C.L., Herman, L.I., Reisner, S.L., Pardo, 
S.T., Sharp, C., Babcock, J.C. 2015. Testosterone 
treatment and MMPI–2 improvement in 
transgender men: a prospective controlled 
study. J Consult Clin Psychol  83(1): 143-56.
Khobzi Rotondi, N. 2012. Depression in trans people: 
a review of the risk factors. Int J Transgend 13(3): 
104-16. 
Kirkbride, J.B., Errazuriz, A., Croudace, T.J., Morgan, 
C., Jackson, D., Boydell, J., Murray, R. M., Jones, 
P.B. 2012. Incidence of schizophrenia and other 
psychoses in england, 1950–2009: a systematic 
review and meta-Analyses. PloS One 7(3): 
e31660. 
Levine, S.B. 2009. Real-life test experience: 
recommendations for revisions to the standards 
of care of the world professional association for 
transgender health.  Int J Transgend 11(3): 186-
93. 
Mc Ewen, B.S. 2001. Invited review: estrogens effects 
on the brain: multiple sites and molecular 
mechanisms. J Appl Physiol 91(6): 2785-801. 
Mohammadi, M.R., Khaleghi, A. 2018. 
Transsexualism: a different viewpoint to brain 
changes. Clin Psychopharmacol Neurosci 
16(2): 136-43.
Moore, E., Wisniewski, A., Dobs, A. 2003. Endocrine 
treatment of transsexual people: a review of 
treatment regimens, outcomes, and adverse 
effects. J Clin Endocrinol Metab 88(8): 3467-73.
Mueller, S.C., Landré, L., Wierckx, K., T’sjoen, G. 
2017. A structural magnetic resonance imaging 
study in transgender persons on cross-sex 
hormone therapy. Neuroendocrinology 105(2): 
123-30.
Nguyen, H.B., Loughead, J., Lipner, E., Hantsoo, L., 
Kornfield, S.L., Epperson, C.N. 2018. What has 
sex got to do with it? the role of hormones in the 
22
Med & Health Jun 2019;14(1): 1-22 Ling S.L. et al.
transgender brain.  Neuropsychopharmacology 
44(1): 22-37. 
O’connor, D.B., Archer, J., Hair, W.M., Wu, F.C. 2002. 
Exogenous testosterone, aggression, and mood 
in eugonadal and hypogonadal men. Physiol 
Behav 75(4): 557-66.
Prince, V.   2005.   Sex vs. Gender.  Int J Transgend 
8(4): 29-32.
Rhoades, R., Tanner, G. 2003. Medical Physiology 
2nd Edition. Lippincott Williams & Wilkins 
343(372-374).
Savic, I., Garcia-Falgueras, A., Swaab, D.F. 2010. 
Sexual differentiation of the human brain 
in relation to gender identity and sexual 
orientation. Prog Brain Res  186: 41-62. 
Seiger, R., Hahn, A., Hummer, A., Kranz, G.S., 
Ganger, S., Woletz, M., Kraus, C., Sladky, 
R., Kautzky, A., Kasper, S., Windischberger, 
C., Lanzenberger, R. 2016. Subcortical gray 
matter changes in transgender subjects after 
long-term cross-sex hormone administration. 
Psychoneuroendocrinology 74: 371-9.
Slabbekoorn, D., Van Goozen, S.H., Megens, 
J., Gooren, L.J., Cohen-Kettenis, P.T. 1999. 
Activating effects of cross-sex hormones on 
cognitive functioning: a study of short-term 
and long-term hormone effects in transsexuals. 
Psychoneuroendocrinology 24(4): 423-47.
Spizzirri, G., Duran, F.L.S., Chaim-Avancini, T.M., 
Serpa, M.H., Cavallet, M., Pereira, C.M.A., 
Santos, P.P., Squarzoni, P., da Costa, N.A., 
Busatto, G.F., Abdo, C.H.N. 2018. Grey and 
white matter volumes either in treatment-naïve 
or hormone-treated transgender women: a 
voxel-based morphometry study. Sci Rep 8(1): 
736.
Swaab, D.F., Fliers, E. 1985. A sexually dimorphic 
nucleus in the human brain. Science 228(4703): 
1112-5.
Swaab, D.F. 2004. Sexual differentiation of the 
human brain: relevance for gender identity, 
transsexualism and sexual orientation. Gynecol 
Endocrinol 19(6): 301-12.
Tee, B.C., Ahmad Rasidi, M.S., Mohd Rushdan, M.N., 
Ismail, A., Sidi, H. 2014. The prevalence and risk 
factors of sexual dysfunction in gynaecological 
cancer patients. Med Health 9(1): 53-61.
Trotman, H.D., Holtzman, C.W., Ryan, A.T., 
Shapiro, D.I., MacDonald, A.N., Goulding, 
S.M., Brasfield, J.L., Walker, E.F. 2013. The 
development of psychotic disorders in 
adolescence: a potential role for hormones. 
Horm Behav 64(2): 411-9. 
Unger, C.A. 2017. Update on gender-affirming 
treatment for the transgender woman. Semin 
Reprod Med 35(5): 442-7.
Van Goozen, S.H., Cohen-Kettenis, P.T., 
Gooren, L.J., Frijda, N.H., Van de Poll, N.E. 
1995. Gender differences in behaviour: 
activating effects of cross-sex hormones. 
Psychoneuroendocrinology  20(4): 343-63.
Webb, R., Safer, J.D. 2019. Transgender hormonal 
treatment.  dlm. yen and jaffe’s reproductive 
endocrinology (Eighth Edition); 709-16.
Weickert, T.W., Allen, K.M., Weickert, C.S. 2016. 
Potential role of oestrogen modulation in 
the treatment of neurocognitive deficits in 
schizophrenia. CNS drugs 30(2): 125-33.
Wierckx, K., Mueller, S., Weyers, S., Van Caenegem, 
E., Roef, G., Heylens, G., T’Sjoen, G. 2012. 
Long-term evaluation of cross-sex hormone 
treatment in transsexual persons. J Sex Med 
9(10): 2641-51.
Zitzmann, M., Nieschlag, E. 2001. Testosterone 
levels in healthy men and the relation to 
behavioural and physical characteristics: facts 
and constructs.  Eur J Endocrinol 144(3): 183-97.
Zucker, K.J. 1985. Cross-gender-identified children. 
In: Steiner B.W. (eds) Gender Dysphoria. 
Perspectives in Sexuality (Behavior, Research, 
and Therapy). Springer, Boston, MA; 75-174. 
Received: 18 Feb 2019
Accepted: 27 Mar 2019
